Multispecific drug design faces growing complexity as more binding arms increase molecular options

The industry is seeing a rapid rise in complex biologic formats such as trispecific antibodies and cell-engaging molecules. As these multispecific constructs multiply, drug developers are turning to discovery and engineering partners to help navigate the expanding design space.

Each additional binding arm creates a combinatorial increase in possible configurations, turning molecule selection into a highly intricate exercise. Determining the optimal combination of targets, affinities, and structural architecture is becoming increasingly challenging.

Service providers are now extending beyond simple antibody generation to offer strategic guidance on format choice, affinity profiling, and manufacturability. Their role includes helping sponsors balance efficacy, safety, and developability considerations early in the design process.

The trend follows the earlier wave of bispecifics that gained attention as Chinese biotech firms launched many programs between 2020 and 2025. The next generation-trispecifics and T-cell engagers-continues to push the limits of molecular engineering.